gbma hails biosimilar tick novo nordisk pharmacy focus · friday 21 aug 2015 pamacday.cm.au...

2
Friday 21 Aug 2015 PHARMACYDAILY.COM.AU Pharmacy Daily Friday 21st August 2015 t 1300 799 220 w www.pharmacydaily.com.au page 1 Novo Nordisk pharmacy focus DIABETES specialist Novo Nordisk has set its sights firmly on the Australian pharmacy market, with an update yesterday confirming the company has ambions to partner more effecvely with pharmacies. As well as working to opmise acvity under exisng professional programs such as MedsCheck, the NDSS and medicaon reviews, Novo Nordisk believes there’s potenal for new areas of collaboraon, as pharmacy evolves its role in primary care and with the strong focus on professional services in the Sixth Community Pharmacy Agreement. The diabetes pandemic means that there are many Australians on the cusp of developing the condion, and if pharmacies can get involved in managing these paents and encouraging diet and exercise it could push them away from type 2 diabetes. “Pharmacy is so well placed to do this screening,” according to a presentaon from Novo Nordisk in Sydney yesterday. The company is also acvely seeking new partnership opportunies with pharmacies, and is inving pharmacists with ideas to make contact to explore possibilies. Novo Nordisk is one of the largest suppliers of insulin for the world market, with other areas of focus including obesity, haemophilia and growth disorders. Pictured above at yesterday’s event are, from leſt: Andrew Rolls, Novo Nordisk (NN) senior product manager, Endocrine; Maxine Hogan, NN naonal key account development manager; and former Guild President Kos Sclavos, Sinapse senior health strategist. GBMA hails biosimilar tick HOSPIRA has announced that Inflectra (infliximab), biosimilar to Janssen-Cilag’s Remicade, has been registered in Australia. As the first monoclonal anbody to be approved, the registraon potenally paves the way for the government to reduce the cost of some of the most costly drugs on the PBS, with Remicade alone coming in at around $100m a year. Inflectra has been registered in Australia for the treatment of eight inflammatory condions: rheumatoid arthris (RA); psoriac arthris; ankylosing spondylis (AS); adult and paediatric Crohn’s disease; refractory fistulising Crohn’s disease; adult and paediatric ulcerave colis; and plaque psoriasis. The PBAC is also considering a PBS lisng for Inflectra, with a recommendaon expected today. The Generic and Biosimilar Medicines Associaon (GBMA) has welcomed the approval as a landmark event for the biologicals market presently worth $2.3b in Australia equivalent to 25% of annual PBS expenditure. “The approval of biosimilar infliximab is great news for paents as it provides an addional treatment opon for those living with some of the most debilitang autoimmune diseases and will create savings allowing greater access to newer, more expensive medicines,” said GBMA ceo Belinda Wood. “Importantly, the approval of biosimilar infliximab increases the TGA’s experience in appropriately evaluang biosimilars, including extrapolang indicaons from the reference biological medicine. “This is essenal if Australia is to unlock the full value offered by biosimilars,” she added. Clinical trial FAQs THE Therapeuc Goods Administraon (TGA) has posted an update of its frequently asked quesons (FAQs) relang to clinical trials which need to access unapproved therapeuc goods. See www.tga.gov.au. NZ OTC NSAID labels THE New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has decided to align with the Australian Therapeuc Goods Administraon oral diclofenac labelling requirements due to implemented by 01 July 2016 (PD 12 Jun) following extensive public consultaon (PD 11 May). The new labelling will reflect, but not necessarily be idencal to, the Australian requirements that refer to allergic reacons to non-steroidal in-inflammatory drugs, pregnancy warnings, length of treatment, dosing maximum, kidney and heart warnings. See www.medsafe.govt.nz for more informaon on the outcome of the diclofenac consultaon.

Upload: others

Post on 29-Sep-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

  • Friday 21 Aug 2015 PHARMACYDAILY.COM.AU

    Pharmacy Daily Friday 21st August 2015 t 1300 799 220 w www.pharmacydaily.com.au page 1

    Novo Nordisk pharmacy focus

    Diabetes specialist Novo Nordisk has set its sights firmly on the Australian pharmacy market, with an update yesterday confirming the company has ambitions to partner more effectively with pharmacies.

    As well as working to optimise activity under existing professional programs such as MedsCheck, the NDSS and medication reviews, Novo Nordisk believes there’s potential for new areas of collaboration, as pharmacy evolves its role in primary care and with the strong focus on professional services in the Sixth Community Pharmacy Agreement.

    The diabetes pandemic means that there are many Australians on the cusp of developing the condition, and if pharmacies can get involved in managing these patients and encouraging diet and exercise it could push them away

    from type 2 diabetes.“Pharmacy is so well placed to

    do this screening,” according to a presentation from Novo Nordisk in Sydney yesterday.

    The company is also actively seeking new partnership opportunities with pharmacies, and is inviting pharmacists with ideas to make contact to explore possibilities.

    Novo Nordisk is one of the largest suppliers of insulin for the world market, with other areas of focus including obesity, haemophilia and growth disorders.

    Pictured above at yesterday’s event are, from left: Andrew Rolls, Novo Nordisk (NN) senior product manager, Endocrine; Maxine Hogan, NN national key account development manager; and former Guild President Kos Sclavos, Sinapse senior health strategist.

    圀䤀一 䄀 䠀䄀刀䰀䔀夀 伀刀 䄀 䠀伀䰀䤀䐀䄀夀

    䌀䰀䤀䌀䬀 䠀䔀刀䔀 吀伀 䘀䤀一䐀 伀唀吀 䴀伀刀䔀

    GBMA hails biosimilar tickHosPira has announced that

    Inflectra (infliximab), biosimilar to Janssen-Cilag’s Remicade, has been registered in Australia.

    As the first monoclonal antibody to be approved, the registration potentially paves the way for the government to reduce the cost of some of the most costly drugs on the PBS, with Remicade alone coming in at around $100m a year.

    Inflectra has been registered in Australia for the treatment of eight inflammatory conditions: rheumatoid arthritis (RA); psoriatic arthritis; ankylosing spondylitis (AS); adult and paediatric Crohn’s disease; refractory fistulising Crohn’s disease; adult and paediatric ulcerative colitis; and plaque psoriasis.

    The PBAC is also considering a PBS listing for Inflectra, with a

    recommendation expected today.The Generic and Biosimilar

    Medicines Association (GBMA) has welcomed the approval as a landmark event for the biologicals market presently worth $2.3b in Australia equivalent to 25% of annual PBS expenditure.

    “The approval of biosimilar infliximab is great news for patients as it provides an additional treatment option for those living with some of the most debilitating autoimmune diseases and will create savings allowing greater access to newer, more expensive medicines,” said GBMA ceo Belinda Wood.

    “Importantly, the approval of biosimilar infliximab increases the TGA’s experience in appropriately evaluating biosimilars, including extrapolating indications from the reference biological medicine.

    “This is essential if Australia is to unlock the full value offered by biosimilars,” she added.

    Clinical trial FAQstHe Therapeutic Goods

    Administration (TGA) has posted an update of its frequently asked questions (FAQs) relating to clinical trials which need to access unapproved therapeutic goods.

    See www.tga.gov.au.

    NZ OTC NSAID labelstHe New Zealand Medicines and

    Medical Devices Safety Authority (MEDSAFE) has decided to align with the Australian Therapeutic Goods Administration oral diclofenac labelling requirements due to implemented by 01 July 2016 (PD 12 Jun) following extensive public consultation (PD 11 May).

    The new labelling will reflect, but not necessarily be identical to, the Australian requirements that refer to allergic reactions to non-steroidal inti-inflammatory drugs, pregnancy warnings, length of treatment, dosing maximum, kidney and heart warnings.

    See www.medsafe.govt.nz for more information on the outcome of the diclofenac consultation.

    http://pharmacydaily.com.au/click?http://www.ravensrecruitment.com.au/http://pharmacydaily.com.au/click?http://tagcomm.com.au/clients/medadvisor/harleyholiday2http://pharmacydaily.com.au/click?http://bit.ly/PharmDaily-EBhttp://pharmacydaily.com.au/click?http://www.medsafe.govt.nz/consultations/WarningStatementsTopicalDiclofenacMedicinesOUTCOME.asp

  • Friday 21 Aug 2015 PHARMACYDAILY.COM.AU

    Pharmacy Daily is Australia’s favourite pharmacy industry publication. Sign up free at www.pharmacydaily.com.au.Postal address: PO Box 1010, Epping, NSW 1710 Australiastreet address: 4/41 Rawson St, Epping NSW 2121 Australia P: 1300 799 220 (+61 2 8007 6760) F: 1300 799 221 (+61 2 8007 6769)

    Part of the Travel Daily group of publications.

    Publisher: Bruce Piper [email protected]: Mal SmithAdvertising and Marketing: Magda Herdzik [email protected] Manager: Jenny Piper [email protected]

    business events newsPharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.

    Looking for a new way to engage clients and guests at your next conference, product launch or training seminar? Think HOYTS Corporate Solutions! With tiered style seating, high-definition projectors and the latest in surround sound, you can deliver everything at HOYTS – and in a more stimulating environment than traditional venues. Call 1300 345 664 to make your next function a HOYTS experience!Thanks to HOYTS Corporate Solutions you can win two tickets to see any film at your nearest HOYTS cinema. Valid until November 2015 you have plenty of time to see a film of your choice.

    To win, be the first person from VIC or TAS to answer the question correctly. Send your answers to [email protected]

    According to the HOYTS Corporate Solutions website, what are Private Screenings perfect for?

    Congratulations to yesterday’s winner, Michelle McPherson from Sanofi.

    DISPENSARYCORNER

    WELCOME to Pharmacy Daily’s events calendar,

    opportunities to earn CPE and CPD points.

    If you have an upcoming event you’d like us to feature, email [email protected] Aug: Pharmacists in General

    Practice Forum; Sofitel Sydney Wentworth; details at: www.psa.org.au

    25 Aug: Australian Pharmacy Council 2015 Colloquium; Canberra; further details at: www.pharmacycouncil.org.au

    26 Aug: Cardiovascular Update: Atrial Fibrillation and Anticoagulants; St Leonards; visit: www.guild.org.au

    29 Aug: CPD Day; Travelodge Newcastle; more info at: www.psa.org.au

    1 Sep: Work Priorities workshop; Melbourne; more info at: www.cpd.shpa.org.au

    4-5 Sep: The Friendlies’ Conference - 2015; Stamford Grand, Glenelg; more info at: pharmacyconference.com.au

    8 Sep: QCPP Refresher Training; Cairns; info and registration: www.guild.org.au/qldcpd

    9 Sep: CPD Accredited First Aid; Brisbane; info and registration: www.guild.org.au/qldcpd

    10-11 Sep: Australasian Disease Management Association 11th Annual Conference; Brisbane Convention Centre; visit: www.adma.org.au

    12 Sep: CPD Accredited First Aid; Gold Coast; info and registration: www.guild.org.au/qldcpd

    16 Sep: Cardiovascular Update: The Role of Pharmacy; St Leonards; more info at: www.guild.org.au

    Events Calendar

    JOINT PAIN?Vege Caps Australian made

    DOUBLE ACTIONAnti-Inflammatory

    1800 181 323 [email protected]

    NOW ON TV!

    ProViNG there is truly no limit to what scientists can do when they set their minds to it, researchers in the USA have created a “vomit machine” to test how a common virus is spread.

    The pretty much totally gross device (below) aims to answer the question of what happens to norovirus when a sufferer with the gastric disorder blows chunks.

    Norovirus is notorious for spreading like wildfire, particularly in closed environments such as cruise ships or catering halls - but it’s not clear whether it is aerosolised when it is vomited.

    The virus vomit evaluator was created using a range of known “vomit metrics” such as pressure and volume (and perhaps the fact that it ALWAYS contains carrots).

    The scientists from North Carolina State University and Wake Forest University then conducted a series of tests, with the device allowing them to control the “volume, viscosity and pressure of the simulated vomiting incidents”.

    They used jelly to make the laboratory vomit have a good consistency, with the results published in the PLOS ONE journal.

    Yes, the virus has the potential to aerosolise and yes, it can travel a long way, the researchers said.

    Being suspended in the air and subject to air movements, the virus has the potential to travel many metres and land on many surfaces at infectious levels.

    DDS spotlight on breastsDisCounT Drug Stores has this

    month launched a major initiative aiming to highlight breast health, with all of its 115 stores across the country offering clinics where women will be taught how to check their own breasts.

    With the number of Australians with breast cancer set to rise to over 17,000 per year in five years, the project is aiming to encourage regular self-examination at home.

    Customers will be taught by a registered nurse using a silicone breast model, with the clinics designed to be “quick and easy to fit into a busy day” with appointments as short as 15 minutes, according to DDS Professional Services Manager, Casey Clark.

    The cost of running the breast health clinics will be funded entirely by Discount Drug Stores, but consumers will be asked to make a donation to the McGrath

    Foundation, once booked into the clinics, supporting the provision of McGrath Breast Care Nurses in the community.

    Clark said the initiative will teach Australian women how to check their own breasts for changes and explain to them the different signs and risk factors to look out for, without a physical examination being conducted in store.

    “Breast cancer affects people of all ages and in most cases, lumps or changes are discovered by the patient themselves or their own doctor, which is why self examinations are so important,” she said.

    The clinics will run until October and bookings are essential - www.discountdrugstores.com.au.

    ASMI ad seminartHe Australian Self-Medication

    Industry is inviting registrations for its next Therapeutic Goods Advertising Code Seminar, which will be held in Sydney on 23 Sep.

    Attendance costs $595 for ASMI members and $795 for non-members - to register CLiCK HERE.

    Wireless TENS deviceEVoMED’s new Painmate (PD

    Wed) is being offered via the pharmacy channel for $49.95, as a Transcutaneous Electrical Nerve Stimulation (TENS) device which fits in the palm of a patient’s hand.

    Suitable for people aged over 18 the device is completely wireless, and offers 50 treatments before the batteries and gel pads need to be replaced - for more information see www.painmate.com.au.

    http://pharmacydaily.com.au/click?http://www.pharmacydaily.com.au/http://pharmacydaily.com.au/click?mailto:[email protected]://pharmacydaily.com.au/click?mailto:[email protected]://pharmacydaily.com.au/click?mailto:[email protected]://pharmacydaily.com.au/click?http://www.cruiseweekly.com.auhttp://pharmacydaily.com.au/click?http://www.pharmacydaily.com.auhttp://pharmacydaily.com.au/click?http://traveldaily.com.auhttp://pharmacydaily.com.au/click?http://businesseventsnews.com.auhttp://pharmacydaily.com.au/click?http://www.travelbulletin.com.auhttp://pharmacydaily.com.au/click?http://traveldaily.com.au/videoshttp://pharmacydaily.com.au/click?mailto:comp%40pharmacydaily.com.au?subject=http://pharmacydaily.com.au/click?http://corporate.hoyts.com.au/http://pharmacydaily.com.au/click?mailto:info%40pharmacydaily.com.au?subject=http://pharmacydaily.com.au/click?http://www.psa.org.au/archives/3277http://pharmacydaily.com.au/click?http://pharmacycouncil.org.au/content/http://pharmacydaily.com.au/click?http://www.guild.org.au/nsw_branch/guild-training-clinical/guild-clinical/cardiovascular-updatehttp://pharmacydaily.com.au/click?http://www.psa.org.au/download/events/nsw/CPD15-Newcastle_Flyer%20.pdfhttp://pharmacydaily.com.au/click?http://cpd.shpa.org.au/lib/pdf/sems/AIM_Work_priorities_regform.pdfhttp://pharmacydaily.com.au/click?http://pharmacyconference.com.auhttp://pharmacydaily.com.au/click?http://www.guild.org.au/qld_branch/events/guild-education-and-cpd2/upcoming-sessionshttp://pharmacydaily.com.au/click?http://www.guild.org.au/qld_branch/events/guild-education-and-cpd2/upcoming-sessionshttp://pharmacydaily.com.au/click?http://www.adma.org.au/images/Conference_Flyer_2015.pdfhttp://pharmacydaily.com.au/click?http://www.guild.org.au/qld_branch/events/guild-education-and-cpd2/upcoming-sessionshttp://pharmacydaily.com.au/click?http://www.guild.org.au/nsw_branch/guild-training-clinical/guild-clinical/cardiovascular-updatehttp://pharmacydaily.com.au/click?http://www.bloomshealth.com.au/products/green-lipped-mussel-and-turmeric-with-bioptmhttp://pharmacydaily.com.au/click?http://www.discountdrugstores.com.auhttp://pharmacydaily.com.au/click?http://www.discountdrugstores.com.auhttp://pharmacydaily.com.au/click?https://asmi.eventsair.com/tgac-seminar-23-sept-in-sydney/tgac-sydney-septhttp://pharmacydaily.com.au/click?http://www.painmate.com.au